|
1
|
Stachler RJ, Chandrasekhar SS, Archer SM,
Rosenfeld RM, Schwartz SR, Barrs DM, Brown SR, Fife TD, Ford P,
Ganiats TG, et al: Clinical practice guideline: Sudden hearing
loss. Otolaryngol Head Neck Surg. 146:1–35. 2012.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Mirian C and Ovesen T: Intratympanic vs.
systemic corticosteroids in first-line treatment of idiopathic
sudden sensorineural hearing loss. JAMA Otolaryngol Head Neck Surg.
146:421–428. 2020.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Chau JK, Lin JR, Atashband S, Irvine RA
and Westerberg BD: Systematic review of the evidence for the
etiology of adult sudden sensorineural hearing loss. Laryngoscope.
120:1011–1021. 2010.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Pucher B, Sobieska M, Grzegorowski M and
Szydlowski J: Acute phase protein reaction in children suffering
from pseudocroups. Mediators Inflamm. 26:1–7. 2019.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Hsiao SY, Lai YR, Kung CT, Tsai NW, Su CM,
Huang CC, Wang HC, Cheng BC, Su YJ, Lin WC, et al: α 1-acid
glycoprotein concentration as an outcome predictor in adult
patients with sepsis. Biomed Res Int. 2019(3174896)2019.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Hochepied T, Berger FG, Baumann H and
Libert C: α 1-acid glycoprotein: An acute phase protein with
inflammatory and immunomodulating properties. Cytokine Growth
Factor Rev. 14:25–34. 2003.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Fukumori T, Kanayama HO and Raz A: The
role of galectin-3 in cancer drug resistance. Drug Resist Updat.
10:101–108. 2007.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Mo D, Tian W, Zhang HN, Feng YD, Sun Y,
Quan W, Hao XW, Wang XY, Liu XX, Li C, et al: Cardioprotective
effects of galectin-3 inhibition against ischemia/reperfusion
injury. Eur J Pharmacol. 863(172701)2019.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Kitoh R, Nishio SY and Usami SI: Treatment
algorithm for idiopathic sudden sensorineural hearing loss based on
epidemiologic surveys of a large Japanese cohort. Acta Otolaryngol.
140:32–39. 2019.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Alan IS and Alan B: Side effects of
glucocorticoids. In: Pharmacokinetics and adverse effects of
drugs-mechanisms and risks factors. Malangu N (ed). Intechopen,
London, 2017.
|
|
11
|
Jarosz M, Olbert M, Wyszogrodzka G,
Mlyniec K and Librowski T: Antioxidant and anti-inflammatory
effects of zinc. Zinc-dependent NF-κB signaling.
Inflammopharmacology. 25:11–24. 2017.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Kim JY, Hong JY and Kim DK: Association of
sudden sensorineural hearing loss with risk of cardiovascular
disease. JAMA Otolaryngol Head Neck Surg. 144:129–135.
2018.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Cirik AA, Evcimik MF, Ulfer G, Yigitbasi T
and Aktas O: Ischemia-modified albumin levels in patients with
idiopathic sudden sensorineural hearing loss. Turkish J Ear Nose
Throat. 29:21–27. 2019.
|
|
14
|
Rudack C, Langer C, Stoll W, Rust S and
Walter M: Vascular risk factors in sudden hearing loss. Thromb
Haemost. 95:454–461. 2006.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Kim C, Sohn JH, Jang MU, Hong SK, Lee JS,
Kim HJ, Choi HC and Lee JH: Ischemia as a potential etiologic
factor in idiopathic sudden sensorineural hearing loss: Analysis of
posterior circulation arteries. Hear Res. 331:144–151.
2016.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Radaković M, Borozan S, Djelić N, Ivanović
S, Miladinović DĆ, Ristanić M, Spremo-Potparević B and Stanimirović
Z: Nitroso-oxidative stress, acute phase response, and cytogenetic
damage in wistar rats treated with adrenaline. Oxid Med Cell
Longev. 2018(1805354)2018.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Takenaka Y, Fukumori T, Yoshii T, Oka N,
Inohara H, Kim HR, Bresalier RS and Raz A: Nuclear export of
phosphorylated galectin-3 regulates its antiapoptotic activity in
response to chemotherapeutic drugs. Mol Cell Biol. 24:4395–4406.
2004.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Mazurek N, Conklin J, Byrd JC, Raz A and
Bresalier RS: Phosphorylation of the beta-galactoside-binding
protein galectin-3 modulates binding to its ligands. J Biol Chem.
275:36311–36315. 2006.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Califice S, Castronovo V, Bracke M and van
den Brûle F: Dual activities of galectin-3 in human prostate
cancer: Tumor suppression of nuclear galectin-3 vs tumor promotion
of cytoplasmic galectin-3. Oncogene. 23:7527–7536. 2004.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Sanjuán X, Fernández PL, Castells A,
Castronovo V, van den Brule F, Liu FT, Cardesa A and Campo E:
Differential expression of galectin 3 and galectin 1 in colorectal
cancer progression. Gastroenterology. 113:1906–1915.
1997.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Pacis RA, Pilat MJ, Pienta KJ, Wojno K,
Raz A, Hogan V and Cooper CR: Decreased galectin-3 expression in
prostate cancer. Prostate. 44:118–123. 2000.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Xu XC, el-Naggar AK and Lotan R:
Differential expression of galectin-1 and galectin-3 in thyroid
tumors. Potential diagnostic implications. Am J Pathol.
147:815–822. 1995.PubMed/NCBI
|
|
23
|
Bertocchi APF, Campanhole G, Wang PH,
Gonçalves GM, Damião MJ, Cenedeze MA, Beraldo FC, de Paula Antunes
Teixeira V, Dos Reis MA, Mazzali M, et al: A role for galectin-3 in
renal tissue damage triggered by ischemia and reperfusion injury.
Transpl Int. 21:999–1007. 2008.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Lorenzo-Almorós A, Pello A, Aceña Á,
Martínez-Milla J, González-Lorenzo Ó, Tarín N, Cristóbal C,
Blanco-Colio LM, Martín-Ventura JL, Huelmos A, et al: Galectin-3 is
associated with cardiovascular events in post-acute coronary
syndrome patients with type-2 diabetes. J Clin Med.
9(1105)2020.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Wang A, Zhong C, Zhu Z, Xu T, Peng Y, Xu
T, Peng H, Chen CS, Wang J, Ju Z, et al: Serum galectin-3 and poor
outcomes among patients with acute ischemic stroke. Stroke.
49:211–214. 2018.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Doverhag C, Hedtjärn M, Poirier F, Mallard
C, Hagberg H, Karlsson A and Sävman K: Galectin-3 contributes to
neonatal hypoxic-ischemic brain injury. Neurobiol Dis. 38:36–46.
2010.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Zhuang JJ, Zhou L, Zheng YH and Ding YS:
The serum galectin-3 levels are associated with the severity and
prognosis of ischemic stroke. Aging. 13:7454–7464. 2021.PubMed/NCBI View Article : Google Scholar
|
